Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced key leadership changes as company founder Rebecca Taub, M.D., transitions from Chief Medical Officer and President of R&D to Senior Scientific and Medical Advisor, while maintaining her position on the Board of Directors. David Soergel, M.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective April 21, 2025.
Dr. Taub's legacy includes pioneering the development of Rezdiffra™ (resmetirom), the first FDA-approved medicine for treating metabolic dysfunction-associated steatohepatitis (MASH). Under her leadership, Madrigal grew from a small R&D team of fewer than 10 professionals to a commercial-stage biopharma company with over 500 employees across the U.S. and Europe.
Dr. Soergel joins from Novartis, where he served as Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. The company currently has two fully enrolled outcomes studies of Rezdiffra underway.
Madrigal Pharmaceuticals (NASDAQ: MDGL) ha annunciato importanti cambiamenti nella leadership: la fondatrice dell'azienda, la dottoressa Rebecca Taub, passa dal ruolo di Chief Medical Officer e Presidente della Ricerca e Sviluppo a quello di Consigliere Scientifico e Medico Senior, mantenendo però la sua posizione nel Consiglio di Amministrazione. David Soergel, M.D., è stato nominato nuovo Executive Vice President e Chief Medical Officer, con decorrenza dal 21 aprile 2025.
Il lascito della dottoressa Taub include la pionieristica sviluppo di Rezdiffra™ (resmetirom), il primo farmaco approvato dalla FDA per il trattamento della steatoepatite associata a disfunzione metabolica (MASH). Sotto la sua guida, Madrigal è cresciuta da un piccolo team di R&S con meno di 10 professionisti a una società biofarmaceutica in fase commerciale con oltre 500 dipendenti tra Stati Uniti ed Europa.
Il dottor Soergel arriva da Novartis, dove ha ricoperto il ruolo di Executive Vice President e Global Head of Cardiovascular, Renal, and Metabolism Development, supervisionando 10 programmi di sviluppo in fase avanzata nel 2024. Attualmente l'azienda ha in corso due studi sugli esiti clinici di Rezdiffra completamente arruolati.
Madrigal Pharmaceuticals (NASDAQ: MDGL) anunció cambios clave en su liderazgo: la fundadora de la empresa, la Dra. Rebecca Taub, pasa de ser Chief Medical Officer y Presidenta de I+D a Asesora Científica y Médica Senior, manteniendo su posición en el Consejo de Administración. David Soergel, M.D., ha sido nombrado nuevo Vicepresidente Ejecutivo y Chief Medical Officer, con efecto a partir del 21 de abril de 2025.
El legado de la Dra. Taub incluye el desarrollo pionero de Rezdiffra™ (resmetirom), el primer medicamento aprobado por la FDA para tratar la esteatohepatitis asociada a disfunción metabólica (MASH). Bajo su liderazgo, Madrigal creció de un pequeño equipo de I+D con menos de 10 profesionales a una compañía biofarmacéutica en etapa comercial con más de 500 empleados en EE.UU. y Europa.
El Dr. Soergel proviene de Novartis, donde fue Vicepresidente Ejecutivo y Jefe Global de Desarrollo Cardiovascular, Renal y Metabólico, supervisando 10 programas en etapas avanzadas de desarrollo en 2024. Actualmente, la compañía tiene en marcha dos estudios de resultados completamente inscritos de Rezdiffra.
Madrigal Pharmaceuticals (NASDAQ: MDGL)는 주요 리더십 변화를 발표했습니다. 회사 창립자 Rebecca Taub 박사는 최고 의료 책임자 및 연구개발(R&D) 사장직에서 고위 과학 및 의료 고문으로 전환하며 이사회 멤버 자리는 유지합니다. David Soergel 박사는 2025년 4월 21일부터 신임 부사장 겸 최고 의료 책임자로 임명되었습니다.
Taub 박사의 업적으로는 대사 기능 장애 관련 지방간염(MASH) 치료를 위한 FDA 승인 첫 약물인 Rezdiffra™ (resmetirom) 개발 선구자가 포함됩니다. 그녀의 리더십 아래 Madrigal은 10명 미만의 소규모 연구개발팀에서 미국과 유럽에 500명 이상의 직원이 있는 상업 단계의 바이오제약 회사로 성장했습니다.
Soergel 박사는 노바티스에서 부사장 겸 심혈관, 신장 및 대사 개발 글로벌 책임자로 근무하며 2024년에 10개의 후기 단계 개발 프로그램을 총괄했습니다. 현재 회사는 Rezdiffra의 완전 등록된 두 건의 결과 연구를 진행 중입니다.
Madrigal Pharmaceuticals (NASDAQ : MDGL) a annoncé des changements clés dans sa direction : la fondatrice de l’entreprise, le Dr Rebecca Taub, passe du poste de Chief Medical Officer et Présidente de la R&D à celui de Conseillère scientifique et médicale principale, tout en conservant sa place au conseil d’administration. David Soergel, M.D., a été nommé nouveau Vice-Président Exécutif et Chief Medical Officer, à compter du 21 avril 2025.
L’héritage du Dr Taub inclut le développement pionnier de Rezdiffra™ (resmetirom), le premier médicament approuvé par la FDA pour traiter la stéatohépatite associée à une dysfonction métabolique (MASH). Sous sa direction, Madrigal est passé d’une petite équipe R&D de moins de 10 personnes à une entreprise biopharmaceutique en phase commerciale comptant plus de 500 employés aux États-Unis et en Europe.
Le Dr Soergel rejoint Novartis, où il était Vice-Président Exécutif et Responsable mondial du développement cardiovasculaire, rénal et métabolique, supervisant 10 programmes de développement en phase avancée en 2024. L’entreprise mène actuellement deux études d’issue entièrement recrutées sur Rezdiffra.
Madrigal Pharmaceuticals (NASDAQ: MDGL) gab wichtige Führungswechsel bekannt: Die Firmengründerin Dr. Rebecca Taub wechselt von der Position als Chief Medical Officer und Präsidentin der F&E zur Senior Scientific and Medical Advisor, behält jedoch ihren Sitz im Vorstand. David Soergel, M.D. wurde zum neuen Executive Vice President und Chief Medical Officer ernannt, mit Wirkung zum 21. April 2025.
Dr. Taubs Vermächtnis umfasst die Pionierarbeit bei der Entwicklung von Rezdiffra™ (Resmetirom), dem ersten von der FDA zugelassenen Medikament zur Behandlung der metabolisch assoziierten Steatohepatitis (MASH). Unter ihrer Führung wuchs Madrigal von einem kleinen F&E-Team mit weniger als 10 Mitarbeitern zu einem biopharmazeutischen Unternehmen in der kommerziellen Phase mit über 500 Mitarbeitern in den USA und Europa.
Dr. Soergel kommt von Novartis, wo er als Executive Vice President und Global Head of Cardiovascular, Renal, and Metabolism Development tätig war und 2024 zehn späte Entwicklungsprogramme leitete. Das Unternehmen führt derzeit zwei vollständig eingeschriebene Outcome-Studien zu Rezdiffra durch.
- First FDA-approved medicine for MASH treatment (Rezdiffra)
- Company expansion to 500+ employees across U.S. and Europe
- Two fully enrolled outcomes studies in progress
- Successful transition from R&D to commercial-stage company
- None.
Dr. Taub’s pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH
CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Medical Officer, and President of Research & Development (R&D), will transition to the role of Senior Scientific and Medical Advisor. Dr. Taub will continue to serve on Madrigal's Board of Directors. Succeeding her, David Soergel, M.D., has been appointed Executive Vice President, Chief Medical Officer, effective April 21, 2025.
After teaching Genetics and Medicine at the University of Pennsylvania, where she was one of the youngest women at that time to become a fully tenured Professor, Dr. Taub moved into senior R&D leadership roles at Bristol Myers Squibb and Roche. In 2011, she co-founded Madrigal with a vision to address unmet medical needs for patients with serious liver and cardiometabolic diseases. Under her leadership, the company achieved an unprecedented milestone – the development of the first FDA-approved medicine for the treatment of MASH, Rezdiffra™ (resmetirom).
"Becky's visionary leadership and relentless commitment have been instrumental in Madrigal's success and the success of the MASH field," said Bill Sibold, Chief Executive Officer of Madrigal. "Her pioneering work as both a scientist and entrepreneur led to the development and approval of Rezdiffra – the first-ever FDA-approved medicine for MASH – bringing real hope to patients who previously had no options. We are incredibly grateful for her contributions and are fortunate to have her continued guidance as a strategic advisor and Madrigal board member. Becky represents the best of what our industry is capable of, and I hope her story will serve as an inspiration for people beginning their careers in biopharma."
“As Becky moves into her new role, we’re thrilled to welcome David Soergel to Madrigal,” said Sibold. “Dave brings more than 20 years of leadership experience in metabolic and cardiovascular disease drug development, spanning both biotech and large pharma. As we look to build a pipeline beyond Rezdiffra, Dave’s deep clinical development expertise and strong track record of advancing therapies across multiple therapeutic areas is exactly the kind of experience that aligns with where we’re taking the company.”
“I’d like to thank my colleagues, our research partners, and the many patients in the MASH community who have made invaluable contributions to Madrigal’s success,” said Dr. Taub. “What started as a small team of fewer than 10 R&D professionals in Conshohocken, PA is now a commercial-stage biopharma company with more than five hundred employees across the U.S. and Europe. I look forward to supporting Dave in my role as a scientific and medical advisor as Madrigal enters its next phase.”
Dr. Soergel joins Madrigal from Novartis, where he served as the Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. At Novartis, Dave led teams that designed and implemented evidence generation programs supporting the expansion of Entresto’s indications and uses. Additionally, he advanced novel medicines to approval for cardiovascular and renal diseases, including Leqvio, Fabhalta and Vanrafia, and served as the development lead for the acquisitions of the Medicines Company and Chinook Therapeutics. Prior to Novartis, Dr. Soergel held leadership roles at biotechnology companies, including Senior Vice President of Clinical Development and Chief Medical Officer at Trevena, where he was responsible for the development of novel treatments for pain and other conditions. He began his career in early-stage clinical development and translational medicine at GlaxoSmithKline. Dr. Soergel trained in pediatrics, pediatric cardiology, and heart failure and transplant at Johns Hopkins Hospital and the Children's Hospital of Philadelphia.
“It is a great privilege to be succeeding Becky as Chief Medical Officer and I look forward to tapping into her expertise and guidance as I begin my new role at Madrigal,” said Dr. Soergel. “I’m excited to be joining an R&D team that delivered the first approved therapy in a disease that has been a major challenge for drug development. With two fully enrolled outcomes studies of Rezdiffra underway, Madrigal is at the forefront of scientific innovation in MASH, and the company is well-positioned to build on its leadership position through pipeline expansion.”
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to Madrigal’s plans to expand its pipeline. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; Madrigal’s ability to enter into any strategic transactions to expand its pipeline and its ability to complete any such transactions; risks of obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; the challenges with the commercial launch of a new product, particularly for a company that does not have commercial experience; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action; enrollment and trial conclusion uncertainties; market demand for and acceptance of Rezdiffra; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive trials; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission(“SEC”), for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Dr. David Soergel start as the new CMO of Madrigal Pharmaceuticals (MDGL)?
What is Madrigal Pharmaceuticals' (MDGL) breakthrough drug for MASH treatment?
How has Madrigal Pharmaceuticals (MDGL) grown under Dr. Rebecca Taub's leadership?
What ongoing clinical studies does Madrigal Pharmaceuticals (MDGL) have for Rezdiffra?
